Dimerix Phase 3 data reading should be out soon!

Dimerix (ASX:DXB)

 

We spoke with Dr Nina Webster, CEO of Dimerix (ASX: DXB), about the excellent economics behind DMX-200 for Focal Segmental Glomulerosclerosis (FSGS) and the near-term nature of the programme, with the first interim data from the current Phase 3 reading out shortly.

Check out the deep-dive research from Pitt Street Research here!

Also check our earlier interview with Dimerix here.

 

What are the Best ASX Life Sciences Stocks to invest in right now?

Check our ASX buy/sell tips